Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Carcinoid tumour; Neuroendocrine carcinoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 27 Oct 2016 Status changed from suspended to active, no longer recruiting.